10 facts about ezetimibe Review article
Article Sidebar
Published:
Mar 31, 2019
Keywords:
dyslipidaemia, ezetimibe, combination therapy
Main Article Content
Abstract
Ezetimibe has a different mechanism of lipid-lowering action than statins, does not interact with substances metabolized by cytochrome P450, increases the hypolipemic effect of any statin and improves the cardiovascular outcome. It is used as a second-line drug in combination with statins, when the therapeutic target has not been achieved despite the administration of a maximum tolerated dose of statin or in patients with intolerance to statins or contraindications to their use.
Article Details
How to Cite
Barylski , M. (2019). 10 facts about ezetimibe. Medycyna Faktow (J EBM), 12(1(42), 55-58. https://doi.org/10.24292/01.MF.0418.16
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Sweeney M.E., Johnson R.R.: Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Exp. Opin. Drug. Metabol. Toxicol. 2007; 3: 441-450.
2. Pikto-Pietkiewicz W., Pasierski T.: Ezetymib – inhibitor wchłaniania cholesterolu. Kardiol. Pol. 2006; 64: 1434-1441.
3. Cagne C., Bays H.E., Weiss S.R. et al.: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 2002; 90: 1084-1091.
4. Davidson M.R., McGarry T., Bettis R. et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Am. J. Coll. Cardiol. 2002; 40: 2125-2134.
5. Catapano A.L., Graham I., De Backer G. et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016; 37(39): 2999-3058.
6. Barylski M.: W parze skuteczniej i bezpieczniej, czyli kiedy ezetymib staje się nieocenionym partnerem w terapii dyslipidemii. Choroby Serca i Naczyń 2018; 15(1): 1-9.
7. Charakterystyka Produktu Leczniczego Ezetrol, 10 mg, tabletki, 25.07.2018.
8. Bardini G., Giorda C.B., Pontiroli A.E. et al.: Ezetimibe + simwastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Diabetology 2010; 9: 20-28.
9. Ballantyne C.M., Weiss R., Moccetti T. et al.: Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). Am. J. Cardiol. 2007; 99: 673-680.
10. Bays H.E., Davidson M.H., Massaad R. et al.: Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am. J. Cardiol. 2011; 108: 523-530.
11. Cannon C.P., Blazing M.A., Giugliano R.P. et al.; IMPROVE-IT Investigators.: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med. 2015; 372: 2387-2397.
12. Farnier M., Freeman M.W., Macdonell G. et al.: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 2005; 26: 897-905.
13. Pearson T.A., Denke M.A., McBride P.E. et al.: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. 2005; 80: 587-595.
2. Pikto-Pietkiewicz W., Pasierski T.: Ezetymib – inhibitor wchłaniania cholesterolu. Kardiol. Pol. 2006; 64: 1434-1441.
3. Cagne C., Bays H.E., Weiss S.R. et al.: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 2002; 90: 1084-1091.
4. Davidson M.R., McGarry T., Bettis R. et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Am. J. Coll. Cardiol. 2002; 40: 2125-2134.
5. Catapano A.L., Graham I., De Backer G. et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016; 37(39): 2999-3058.
6. Barylski M.: W parze skuteczniej i bezpieczniej, czyli kiedy ezetymib staje się nieocenionym partnerem w terapii dyslipidemii. Choroby Serca i Naczyń 2018; 15(1): 1-9.
7. Charakterystyka Produktu Leczniczego Ezetrol, 10 mg, tabletki, 25.07.2018.
8. Bardini G., Giorda C.B., Pontiroli A.E. et al.: Ezetimibe + simwastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Diabetology 2010; 9: 20-28.
9. Ballantyne C.M., Weiss R., Moccetti T. et al.: Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). Am. J. Cardiol. 2007; 99: 673-680.
10. Bays H.E., Davidson M.H., Massaad R. et al.: Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am. J. Cardiol. 2011; 108: 523-530.
11. Cannon C.P., Blazing M.A., Giugliano R.P. et al.; IMPROVE-IT Investigators.: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med. 2015; 372: 2387-2397.
12. Farnier M., Freeman M.W., Macdonell G. et al.: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 2005; 26: 897-905.
13. Pearson T.A., Denke M.A., McBride P.E. et al.: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. 2005; 80: 587-595.